This Week in Critical Care — Jul 31, 2026

Welcome to This Week in Critical Care. This week we're covering 10 notable papers spanning individualized physiological monitoring, optimization of shock resuscitation, and the clinical and human complexities of advanced life support. Let's dive in.

In acute brain injury, managing intracranial hypertension has traditionally relied on rigid, one-size-fits-all parameters. Writing in Intensive Care Medicine, Taccone and colleagues challenge this paradigm in their comprehensive review of intracranial pressure physiology [2]. They explain that while raised intracranial pressure plays a central pathophysiological role as both a consequence and a driver of secondary cerebral insults through mechanical deformation and ischemia, traditional management relying on fixed thresholds, such as twenty-two millimeters of mercury, is increasingly controversial. This is because tolerance to intracranial pressure elevation varies widely across different patients, disease entities, and physiological contexts. The authors detail how determinants like intracranial compliance, cerebrospinal fluid dynamics, cerebral blood volume, and systemic factors dictate individual tolerance. They advocate for a shift toward individualized, physiology-informed management, highlighting emerging concepts such as intracranial pressure burden, waveform morphology, cerebral autoregulation, and functional brain monitoring. Furthermore, they emphasize the complementary role of noninvasive monitoring modalities when invasive options are unavailable or contraindicated, and envision a future where artificial intelligence-based approaches analyze complex multimodal neuromonitoring data to predict secondary insults and guide patient-specific interventions.

This concept of tailoring resuscitation to individual physiology is echoed in the cardiovascular domain. In the American Journal of Respiratory and Critical Care Medicine, Pinsky and colleagues present a physiological framework for assessing tissue perfusion during septic shock resuscitation through the lens of the vascular waterfall [3]. They explain that tissue autoregulation requires not only an adequate upstream mean arterial pressure, but also a sufficient perfusion pressure difference between this mean arterial pressure and the downstream arteriolar critical closing pressure to drive blood flow into the capillaries. In vasoplegic states like septic shock, vascular tone is severely decreased, which can drop the critical closing pressure to a level approximating the mean systemic filling pressure. This abolishes autoregulation even if mean arterial pressure and cardiac output appear normal. Resuscitation must aim to restore these local vascular waterfalls. While initial fluid resuscitation and vasopressors often succeed, they frequently fail to restore microvascular flow. To address this, the authors propose using capillary refill time as a bedside marker of tissue blood flow. If initial resuscitation to standard mean arterial pressure targets does not restore perfusion and the capillary refill time remains greater than three seconds, they suggest performing a vasopressor test to increase the mean arterial pressure target to greater than seventy-five millimeters of mercury. If this increase successfully reduces the capillary refill time to under three seconds, the higher target can be maintained; if not, clinicians should return to prior levels to minimize the risks of iatrogenic vasopressor exposure.

Moving from pathophysiology to clinical epidemiology and quality measures, a major study published in Critical Care by Ford and colleagues examines a decade of SEP-1 compliance and sepsis mortality in the United States [1]. This long-term analysis provides critical context on how standardized regulatory bundles impact patient outcomes across diverse healthcare systems. While compliance with standardized bundles like SEP-1 aims to streamline early care, septic patients often present with complex underlying conditions that complicate standard protocols. For example, in the Journal of Critical Care, Vahldieck and colleagues investigate the safety of terminal complement inhibition during septic shock [6]. In a global propensity score-matched cohort study using the TriNetX database, they analyzed adult patients with septic shock and an underlying indication for C5 inhibition, such as atypical hemolytic uremic syndrome, myasthenia gravis, neuromyelitis optica spectrum disorder, or paroxysmal nocturnal hemoglobinuria, who were treated with eculizumab or ravulizumab. After matching six hundred and thirty-eight patients in each cohort to balance demographics and comorbidities, the researchers found that patients receiving terminal complement inhibition had significantly higher rates of complications. Specifically, complement inhibition roughly doubled the risk of thrombocytopenia, occurring in over twenty percent of treated patients compared to about nine percent of controls, and nearly doubled the risk of acute kidney injury, which occurred in twenty-five percent of the treatment group compared to roughly thirteen percent of controls. Additionally, treated patients experienced a sixty percent increase in the need for renal replacement therapy, a sixty percent increase in thrombotic disorders, and a fifty percent increase in major adverse cardiovascular events. Importantly, thirty-day mortality did not differ between the matched cohorts. These findings suggest that while terminal complement inhibition is increasingly relevant for specific patient populations, it is associated with a substantial burden of renal, hematologic, and thrombotic complications during septic shock.

In addition to systemic immunomodulation, localized infection prevention strategies remain a key focus of intensive care. Writing in Intensive Care Medicine, Schouten and colleagues explore the role of selective decontamination of the digestive tract, or SDD, as an antimicrobial stewardship intervention, highlighting the critical need for a feedback loop to monitor its long-term impact on resistance patterns [8]. Implementing such interventions requires balancing immediate infection prevention with broader ecological consequences in the intensive care unit.

When standard ventilator strategies fail in severe respiratory distress, advanced modalities like extracorporeal membrane oxygenation, or ECMO, are frequently deployed. In Critical Care, B'ünger and colleagues re-evaluate oxygenation targets and oxygen exposure in patients with acute respiratory distress syndrome undergoing veno-venous extracorporeal membrane oxygenation [4]. Determining the optimal balance of oxygen delivery is crucial, particularly as we recognize how patient-specific factors influence mechanical ventilation. This is highlighted in another Critical Care publication by Mohamed and colleagues, which examines the critical intersection of biologic sex and predicted body weight in patients with acute respiratory distress syndrome [5]. This research underscores the importance of refining our ventilatory settings to avoid gender-based disparities in tidal volume delivery and lung protection.

Beyond the physiological and technical parameters of extracorporeal support, the human cost of these highly invasive therapies is receiving much-needed attention. Writing in Chest, Semler and colleagues on behalf of the ECMO Ethics Workgroup explore the profound physical, psychological, and social impacts of ECMO on patients, families, and clinicians [7]. While the literature has historically focused on survival and technical success, this paper highlights the substantial physical and psychological burdens carried by ECMO survivors, as well as the intense psychosocial challenges faced by family members and surrogate decision-makers. The authors also address the moral distress and emotional exhaustion experienced by the bedside clinicians providing this intensive care. To mitigate these unavoidable consequences of advanced life support, the workgroup outlines several best-practice recommendations. These include establishing clear and consistent interdisciplinary communication, implementing structured decision-making frameworks, actively incorporating patient values into care goals, and initiating early ethics and palliative care consultations. They also call for systematic long-term follow-up of survivors and further research into educational interventions for families to help navigate this complex clinical journey.

In our daily management of critically ill patients, pharmacotherapy choices significantly influence hemodynamics and recovery. In the Journal of Critical Care, Malik and colleagues present a retrospective study examining the risk factors and clinical outcomes associated with bradycardia in critically ill patients receiving dexmedetomidine [9]. Given the widespread use of dexmedetomidine for light sedation, understanding which patients are at highest risk for severe bradycardia is essential for safe prescribing and monitoring.

At the same time, managing the profound catabolic and proinflammatory state of critical illness remains an ongoing challenge. In the Journal of Critical Care, Blaskovits and colleagues conducted a systematic review and meta-analysis of anabolic androgen therapy in critically ill adults [10]. Searching major databases up to February twenty-four, twenty-six, they identified four randomized controlled trials comparing anabolic agents, such as testosterone, to placebo or standard care. Assessing the certainty of the evidence using the GRADE approach, the authors found that three of the trials carried some concerns for bias, while one had a high risk of bias. Ultimately, the pooled analysis revealed that the effects of anabolic androgen therapy on patient-important outcomes—including mortality, intensive care unit and hospital lengths of stay, and duration of mechanical ventilation—remain highly uncertain. Consequently, the authors conclude there is currently insufficient evidence to support the routine use of anabolic androgen therapy in the critically ill, and highlight the need for larger, well-designed trials to clarify both its efficacy and safety profile.

If you only have time for one paper this week, make it the physiological framework for assessing tissue perfusion during septic shock resuscitation by Pinsky and colleagues in the American Journal of Respiratory and Critical Care Medicine [3]. This paper provides a highly practical, bedside-applicable approach using capillary refill time and a targeted mean arterial pressure challenge to individualize vasopressor therapy, helping clinicians avoid the iatrogenic harms of excessive vasopressor exposure when microvascular flow cannot be restored.

Here are the key takeaways from this week in Critical Care. First, move away from rigid, threshold-driven management of intracranial hypertension in acute brain injury, and instead transition toward individualized, physiology-informed care that considers intracranial compliance, waveform morphology, and autoregulation. Second, when resuscitating patients in septic shock, consider using a capillary refill time threshold of three seconds to guide a mean arterial pressure challenge; if increasing the mean arterial pressure target above seventy-five millimeters of mercury does not normalize capillary refill, return to prior targets to minimize vasopressor toxicity. Third, be highly vigilant when managing septic shock in patients receiving terminal complement inhibitors like eculizumab or ravulizumab, as these therapies are associated with roughly doubled risks of acute kidney injury and thrombocytopenia, as well as significantly higher rates of thrombotic complications and renal replacement therapy. Fourth, address the profound human impact of extracorporeal membrane oxygenation by implementing structured decision-making frameworks, early palliative care consultation, and systematic long-term follow-up for survivors and their families. And fifth, avoid the routine use of anabolic androgen therapies like testosterone in critically ill patients, as current clinical evidence remains highly uncertain regarding their impact on mortality, length of stay, and ventilator days.

That's your roundup for This Week in Critical Care. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.